Drug intelligence / Profile preview

DZD9008 + carbamazepine

Development stage
Phase 1
Lead developer
Dizal Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two drugs: - **Sunvozertinib (DZD9008):** An orally available, potent, irreversible small molecule inhibitor that selectively targets mutant forms of the epidermal growth factor receptor (EGFR), particularly EGFR exon 20 insertion mutations and also human epidermal growth factor receptor 2 (HER2). It is being developed primarily for non–small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. Sunvozertinib has demonstrated significant anti-tumor activity and a favorable safety profile in clinical trials[1][3][5][6]. - **Carbamazepine:** A well-established small molecule anticonvulsant and mood stabilizer used primarily to treat epilepsy and neuropathic pain. Its mechanism involves inhibition of voltage-gated sodium channels in neuronal membranes.

Brand names
sunvozertinib
Other names
DZD9008DZD-9008DZD 9008sunvozertinibcarbamazepine
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)

Beyond the preview

Go deeper on DZD9008 + carbamazepine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DZD9008 + carbamazepine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call